ArticleInfluenza and other respiratory viruses2012
Maternal outcomes among pregnant women receiving live attenuated influenza vaccine.
Article in Influenza and other respiratory viruses, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Vaccines for preventing influenza in healthy adults.The Cochrane database of systematic reviews · 2018Pooled it
- A systematic review of ethical issues in vaccine studies involving pregnant women.Human vaccines & immunotherapeutics · 2016Pooled it
- A systematic review of adverse events following immunization during pregnancy and the newborn period.Vaccine · 2015Pooled it
- The Live Attenuated Influenza Vaccine in Australia: An Additional Tool for Influenza Prevention.The Medical journal of Australia · 2026Article
- Safety of the Seasonal Influenza Vaccine in 2 Successive Pregnancies.JAMA network open · 2024Article
- Review
- Is the Host Viral Response and the Immunogenicity of Vaccines Altered in Pregnancy?Antibodies (Basel, Switzerland) · 2020Article
- Closer and closer? Maternal immunization: current promise, future horizons.Journal of perinatology : official journal of the California Perinatal Association · 2020Review
- Review
- Maternal vaccination for the prevention of influenza: current status and hopes for the future.Expert review of vaccines · 2016Review
- Surveillance of antenatal influenza vaccination: validity of current systems and recommendations for improvement.BMC public health · 2015Article
- Development of live-attenuated arenavirus vaccines based on codon deoptimization.Journal of virology · 2015Article
- Vaccinations for pregnant women.Obstetrics and gynecology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough the live attenuated influenza vaccine (LAIV) prescribing information contains warnings/precautions against use during pregnancy, administration of LAIV to pregnant women does occur. Data regarding maternal outcomes after LAIV administration during pregnancy are limited.
objectivesMaternal outcomes after LAIV vaccination during pregnancy were examined.
methodsData from a health insurance claims database that covers approximately 50 million individuals were analyzed for the six influenza seasons from 2003-2004 through 2008-2009. Emergency department (ED) visits and hospitalizations occurring within 42 days of vaccination were analyzed by primary diagnosis; outcomes were categorized as cardiopulmonary, obstetric, and other. Cohort characteristics were analyzed using descriptive statistics.
resultsOf 834,999 pregnancies identified, 138 (0·017%) were among women who received LAIV vaccinations. Of the 138 pregnant women, 13% were ≤19 years, 67% were 20-34 years, and 20% were ≥35 years of age. Eight events occurred within 42 days of vaccination: one ED visit for bronchitis, two hospitalizations for hyperemesis gravidarum and premature labor, and five ED visits/hospitalizations for common medical conditions. All outcomes identified after LAIV exposure occurred at rates similar to rates in unvaccinated pregnant women reported in the medical literature.
conclusionsAdministration of LAIV to pregnant women is rare; the rate has remained constant since 2004-2005. In this cohort, there was no evidence of significant maternal adverse outcomes after receipt of LAIV. These data may offer some reassurance to providers and pregnant women in the event of inadvertent LAIV administration, but do not support the routine use of LAIV in pregnant women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.